Alnylam

Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to help patients who have limited or inadequate treatment options live fuller, healthier lives.   Founded in 2002 on the bold vision to turn scientific possibility into reality, Alnylam has a robust discovery platform and deep pipeline of investigational medicines, including several programs in late-stage clinical development.  Patients are at the core of everything we do; their needs drive our discoveries and their stories further our commitment to delivering innovative therapies.

Find out more